Marksans Pharma’s UK Unit Bags MHRA Green Light for Cetirizine Anti-Allergy Solution

’s UK subsidiary, Relonchem, has secured Marketing Authorization from the UK Medicines & Healthcare Products Regulatory Agency (MHRA) for its Cetirizine Dihydrochloride 1 mg/ml oral solution, a widely used anti-allergy medicine targeting both seasonal and perennial allergies. This approval not only broadens Marksans’ regulated-market portfolio, but also demonstrates its growing capabilities in developing and commercializing liquid generics in the UK, reinforcing its position as a globally competitive pharma company. Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.